Burlington, Mass. — Consano Bio has raised more than $15 million in an oversubscribed financing to advance C-1101, its investigational biologic treatment for chronic painful lumbosacral radiculopathy, or chronic sciatica.
The clinical-stage biotechnology company said the financing exceeded its $15 million target and brings the total amount raised since its founding three years ago to more than $45 million.
Proceeds will be used to complete the company’s ongoing randomized, double-blind Phase 1 clinical trial of C-1101 and support further development of the therapy and other pipeline programs.
The study is enrolling patients with chronic sciatica in the United States and Australia. Consano expects enrollment to be completed in early 2027, with clinical data anticipated in the first half of 2027.
The U.S. Food and Drug Administration granted C-1101 Fast Track designation for chronic lumbosacral radiculopathy in August 2026.
“C-1101 represents a new category of disease-modifying biologics, designed to activate cellular repair and alleviate the pain and dysfunction that results from orthopedic conditions,” said Andrew Hall, Chief Executive Officer of Consano Bio.
Hall said the financing will allow the company to complete its first clinical study and evaluate C-1101 against an epidural saline injection in patients with chronic sciatica.
C-1101 is a platelet-derived, multi-protein biologic designed to modulate inflammation and stimulate cellular repair at the site of nerve injury.
The therapy contains cytokines, growth factors and matrix proteins and is administered through an epidural injection to deliver the proteins directly to the affected area.
Consano said there are currently no FDA-approved pharmaceutical treatments specifically for chronic sciatica, which can cause radiating pain, numbness and weakness extending from the lower back into the leg.
